Kura Oncology KURA Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's debt issuance cost amortization?
- Kura Oncology (KURA) reported debt issuance cost amortization of $106K in Q1 2026.
- How has Kura Oncology's debt issuance cost amortization changed year-over-year?
- Kura Oncology's debt issuance cost amortization decreased by 20.3% year-over-year, from $133K to $106K.
- What is the long-term trend for Kura Oncology's debt issuance cost amortization?
- Over 4 years (2021 to 2025), Kura Oncology's debt issuance cost amortization has grown at a 6.6% compound annual growth rate (CAGR), from $399K to $515K.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).